SCHEMBL8276286

SCHEMBL8276286

CC(C)(C)Cc1ccc2c(c1)CCCN2C(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
ALDH1A1 P00352 6/20 0.49
HTT P42858 3/20 0.49
GAA P10253 2/20 0.49
MAPT P10636 2/20 0.49
CASP1 P29466 2/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
KDM4E B2RXH2 2/20 0.46
TMEM97 Q5BJF2 4/20 0.45
SIGMAR1 Q99720 4/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13349382 0.88 ALDH1A1 (0.64) L3MBTL1NPC1RAB9AALDH1A1HTT
SCHEMBL18392314 0.83 RAB9A (0.63) L3MBTL1NPC1RAB9AALDH1A1HTT
SCHEMBL16595915 0.83 NPC1 (0.57) L3MBTL1NPC1RAB9AALDH1A1HTT
SCHEMBL2876191 0.82 NPC1 (0.53) L3MBTL1NPC1RAB9AGAASMN1; SMN2
SCHEMBL16595938 0.82 NPC1 (0.56) L3MBTL1NPC1RAB9AALDH1A1HTT
SCHEMBL27616400 0.81 NPC1 (0.84) L3MBTL1NPC1RAB9AALDH1A1HTT
SCHEMBL16595916 0.80 L3MBTL1 (0.51) L3MBTL1NPC1RAB9AALDH1A1HTT
SCHEMBL2877449 0.80 NPC1 (0.47) L3MBTL1NPC1RAB9AHTTGAA
SCHEMBL2877447 0.80 NPC1 (0.47) L3MBTL1NPC1RAB9AHTTGAA
SCHEMBL5714049 0.80 NPC1 (0.47) L3MBTL1NPC1RAB9AHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100145056-A1 ACETYL 2-HYDROXY-1,3-DIAMINOALKANES JOHN VARGHESE 2010-06-10 US disclosed
US-7544717-B2 2-amino- and 2-thio- substituted 1,3-diaminopropanes ELAN PHARMACEUTICALS, INC. (US) 2009-06-09 US disclosed
US-7244725-B2 Acetyl 2-hydroxy-1, 3-diaminoalkanes ELAN PHARMACEUTICALS, INC. (US) 2007-07-17 US disclosed
WO-2005087714-A2 METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-09-22 WO disclosed
WO-2005087215-A1 SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145056-A1 ACETYL 2-HYDROXY-1,3-DIAMINOALKANES BACE1, BACE2, APP L3MBTL1 1660/4885NPC1 1553/4885RAB9A 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.